Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939326 · ClinicalTrials.gov registry record · Phase 2
Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
A Phase 2 study of Glabellar Frown Lines (GL), sponsored by Bonti.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT02939326: Completed Phase 2 study of Glabellar Frown Lines (GL), sponsored by Bonti.
NCT02939326 is a Phase 2 study of Glabellar Frown Lines (GL) that has completed, run by Bonti. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02939326, a Phase 2 study of Glabellar Frown Lines (GL), has completed, sponsored by Bonti.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).
Primary Outcome
Subjects Achieving a 2 Grade Response At Maximum Frown On Any Study Day By Dose using the Facial Wrinkle Scale (FWS) The FWS is a four-point scale that indicates severity of GL as follows: 0 = none, 1 = mild, 2 = moderate, or 3 = severe. Each scale is a four-point photonumeric scale based on photographs incorporating each aspect to be evaluated in a stepwise manner.
Conditions Studied
Interventions
- DRUG EB-001 injection
- DRUG Placebo injection
Study Locations (2)
California
- Center For Dermatology Clinical Research, Inc. - Fremont
- Steve Yoelin, MD Medical Associates, INC. - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-07-12 |
| Phase | Phase 2 |
What the finished NCT02939326 record still lists
NCT02939326 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Glabellar Frown Lines (GL) appearing as the primary indexed condition, and to 2 interventions - of which EB-001 injection is the first listed.
NCT02939326 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02939326 about?
NCT02939326 is a clinical study titled "Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines". To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).
What is the current status of trial NCT02939326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-12. Estimated completion is 2017-07-12.
What conditions does trial NCT02939326 study?
This clinical trial studies the following conditions: Glabellar Frown Lines (GL).
What interventions are being tested in trial NCT02939326?
The interventions under investigation include: EB-001 injection (DRUG), Placebo injection (DRUG).
Who is sponsoring clinical trial NCT02939326?
This trial is sponsored by Bonti, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02939326 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02939326's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia